Boehringer Ingelheim Opens $77 Million Shanghai Biologics CMO Plant; Establishes R&D Partnership with Peking University

Germany's Boehringer Ingelheim officially opened its $77 million China biologic drug contract manufacturing facility for biologic drugs in Shanghai. The project, which is a joint venture with Shanghai Zhangjiang Biotech and Pharma Base Development, will join BI's three existing biologic CMO facilities, located in Europe and the US. BI also announced a long-term, early science collaboration with Peking University. The collaboration aims to discover new drug candidates for cardiometabolic disease and cancer immunology, using regenerative medicine and gene therapy. More details.... Share this with colleagues: // //